Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2023012531
document
Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes in R/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK+) and ALK-negative (ALK-) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK+ ALCL, and ALK- ALCL (≥18 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The...
Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
Published in: Journal of Cancer Survivorship
Access to document
10.1007/s11764-022-01305-w
document
Purpose: Little is known about the employment situation of long-term Hodgkin lymphoma (HL) survivors despite their young age at diagnosis and the favorable prognosis of the disease. In this cross-sectional study, we aim to describe the employment situation in a cohort of long-term HL survivors compared to the general population and investigate the associations with disease characteristics and treatment exposure. Methods: HL survivors > 25 years (n = 1961) were matched 1:25 to controls (n = 49,025) from the European Union Labour Force Survey. Individual treatment information was obtained...
Sidsel J. Juul, Sára Rossetti, Michal Kicinski, Marleen A.E. van der Kaaij, Francesco Giusti, Paul Meijnders, Berthe M.P. Aleman, John M.M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Marc André, Fabien Le Bras, Wouter J. Plattel, Michel Henry-Amar, Martin Hutchings, Maja V. Maraldo
Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
Published in: BMC Cancer
Access to document
10.1186/s12885-024-12191-z
document
BACKGROUND: Primary central nervous system lymphoma (PCNSL) are rare mature B-cell lymphoproliferative diseases characterized by a high incidence of MYD88 L265P and CD79B Y196 hotspot mutations. Diagnosis of PCNSL can be challenging. The aim of the study was to analyze the detection rate of the MYD88 L265P and CD79B Y196 mutation in cell free DNA (cfDNA) in plasma of patients with PCNSL. METHODS: We analyzed by digital droplet PCR (ddPCR) to determine presence of the MYD88 L265P and CD79B Y196 hotspot mutations in cfDNA isolated from plasma of...
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands
Published in: Haematologica
Access to document
10.3324/haematol.2023.283174
document
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of mature T-cell neoplasms with an unfavorable prognosis; presentation with stage I(E) disease is uncommon. In clinical practice, an abbreviated chemotherapy treatment regimen combined with radiotherapy (combined modality treatment (CMT)) is commonly used, although evidence from clinical trials is lacking. The aim of this nationwide population-based cohort study is to describe first-line treatment and outcome of patients with stage I(E) PTCL. All newly diagnosed patients ≥ 18 years with stage I(E) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL)...
Frederik O Meeuwes, Mirian Brink, Wouter Plattel, Marjolein W M Van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Karen J Neelis, Anne P G Crijns, Laurien A Daniëls, Tjeerd J F Snijders, Joost S P Vermaat, Gerwin A Huls, Marcel Nijland
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma
Published in: ESMO Open
Access to document
10.1016/j.esmoop.2024.102248
document
Background: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors. Methods: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using...
Y. M. Geurts, S. I.M. Neppelenbroek, B. M.P. Aleman, C. P.M. Janus, A. D.G. Krol, D. J. van Spronsen, W. J. Plattel, J. M. Roesink, K. M.S. Verschueren, J. M. Zijlstra, H. R. Koene, M. R. Nijziel, E. C. Schimmel, E. de Jongh, F. Ong, L. C.J. te Boome, R. S. van Rijn, L. H. Böhmer, B. D.P. Ta, H. P.J. VisserE. F.M. Posthuma, Y. M. Bilgin, K. Muller, D. van Kampen, C. So-Osman, J. S.P. Vermaat, R. J. de Weijer, M. J. Kersten, F. E. van Leeuwen, M. Schaapveld